The development of any topical therapeutic compound requires robust safety testing before clinical deployment. One of the foundational assessments in this process is the in vitro toxicity study, which simulates how human cells respond to repeated or high-dose exposure to active ingredients. In 2018, a comprehensive in vitro toxicity study of ION-ZCM1 was conducted using the MTT cytotoxicity assay, confirming its safety for epidermal application, even at high concentrations.
This research, completed by the University of Debrecen and INDEVION Biotechnology Research, focused on the HACAT human keratinocyte cell line, which closely mimics the behavior of skin cells. The findings reinforce the clinical viability of ION-ZCM1 as a biocompatible ion complex used in Ion Gel ZCM-25®, especially in formulations intended for sensitive skin, wound care, and post-operative recovery.
The in vitro toxicity study used the gold-standard MTT assay, a colorimetric test that assesses the mitochondrial function and viability of living cells. This method is widely adopted in toxicology for its ability to provide quantifiable data on how a compound affects cellular metabolism. A lack of dye conversion indicates metabolic disruption, while a full color change confirms that the cells remain viable and functional.
These results indicate that ION-ZCM1, at therapeutic strength, does not harm skin cells and can be safely applied topically.
The in vitro toxicity study used the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), which is highly sensitive to disruptions in cellular respiration. As an indirect measure of toxicity, the MTT test offers clear insight into whether a compound compromises mitochondrial function or metabolic energy generation in eukaryotic cells.
MTT is especially valuable for testing skincare or wound treatment ingredients, where dermal tolerability is paramount. The assay helped determine that ION-ZCM1 maintains cell integrity even in direct contact with human epidermal cells.
This in vitro toxicity study confirmed that ION-ZCM1 does not cause adverse reactions when applied to human skin models. The HACAT line was selected for its reliability and relevance in dermatological testing. The results were consistent with expectations for a topically safe, redox-active compound.
These qualities contributed to the absence of mitochondrial damage in the test, validating ION-ZCM1’s use in therapeutic topical systems.
The positive results of the in vitro toxicity study support the inclusion of ION-ZCM1 in a range of clinical formulations:
ION-ZCM1 can be safely applied to compromised skin in diabetic ulcers, pressure sores, or post-debridement sites, as its safety has been confirmed even on sensitive keratinocyte lines.
Patients recovering from incisions or dermatological procedures benefit from non-irritating topical agents. The in vitro toxicity study results suggest Ion Gel ZCM-25® can support healing without triggering inflammation.
Redox imbalance and oxidative stress are common in inflammatory skin conditions. ION-ZCM1’s safety profile makes it suitable for long-term use in atopic dermatitis or eczema treatments.
In addition to the in vitro toxicity study, several other safety evaluations were performed to validate the overall tolerability of ION-ZCM1:
Together, these confirm that the observations of the in vitro toxicity study translate into clinical relevance.
Unlike synthetic drugs or heavy metals, ION-ZCM1’s ions are found naturally in the body and play roles in enzymatic function, mitochondrial respiration, and immune modulation. The in vitro toxicity study confirms that the delivery of these ions via ligand-bound aqueous complexes does not disturb the cellular environment.
In fact, by supporting redox homeostasis, ION-ZCM1 may enhance cell resilience in stress-prone environments like wounds, burns, and surgical sites.
| Parameter | Value |
|---|---|
| Test system | HACAT human keratinocytes |
| Assay type | MTT (colorimetric mitochondrial viability) |
| ION-ZCM1 concentration tested | 25% (therapeutic level) |
| Cytotoxicity | None observed |
| Result | High metabolic activity; no damage |
| Formulation notes | No ethanol, no excipients, pH-balanced |
| Relevance | Dermatology, wound care, and post-surgical use |
The outcome of the in vitro toxicity study supports regulatory submissions for:
These findings also support the scalability of Ion Gel ZCM-25® as a product safe for both hospital and outpatient care.
The 2018 in vitro toxicity study conducted on ION-ZCM1 using the MTT cytotoxicity assay confirms the compound’s exceptional tolerability at therapeutic topical doses. The use of HACAT cells provided a direct model for human epidermal exposure, and the outcome—no cytotoxicity observed—places ION-ZCM1 among the most dermally safe ion-based formulations tested to date.
With complementary animal and clinical studies reinforcing these findings, ION-ZCM1 is well-positioned for broad application in sensitive skin therapies, wound healing, and anti-inflammatory topical interventions. This safety benchmark allows for confident deployment in acute and long-term treatment settings.
Full in vitro toxicity study and lab report available at:
https://zcm25.com/invitro-toxicity-study-of-ion-zcm1-on-human-cells-using-an-mtt-cytotoxicity-test-method
Explore additional safety and toxicology data:
https://zcm25.com/resources